University of Oklahoma opens oncology science faculty search with 5-year start-up support
The newly established Department of Oncology Science at the University of Oklahoma Health Sciences Center is recruiting assistant, associate, and full professors, signaling a broad institutional push into cancer biology at multiple career stages. The search is tied to the NCI-designated OU Health Stephenson Cancer Center, giving the incoming faculty access to an established cancer center environment rather than a stand-alone departmental appointment. In practical terms, the post is aimed at investigators who can build independent programs while plugging into interdisciplinary work already underway on campus.
The scientific scope is explicit and deliberately wide. Investigators in cancer metabolism, cancer signaling, epigenetics, tumor immunology, and chemical biology are being courted, with additional interest in cancer biology programs that intersect with diabetes, aging, and neurosciences. That breadth matters because modern oncology increasingly depends on mechanisms that reach beyond a single pathway: metabolic rewiring can sustain proliferation, epigenetic drift can stabilize malignant cell states, immune escape can blunt host defense, and aberrant signaling can keep these processes coordinated. A department built around those interfaces is positioning itself for mechanistic work that can travel from basic discovery to therapeutic hypothesis generation.
The appointment is open to candidates with a PhD, MD, or MD/PhD in biomedical sciences, and the hiring language makes clear that a strong publication record in high-impact journals will be a major expectation. Applicants with NCI funding are especially encouraged, which is a straightforward way to filter for investigators who have already demonstrated independent grant competitiveness. The department is also looking for scientists who can manage and sustain their own research programs, not just contribute to collaborative projects. In an academic cancer center, that combination usually means two things at once: a proven publication trajectory and enough conceptual depth to build a lab or clinical-translational program that will stand on its own.
A 5-year start-up package is part of the offer. While the posting does not define a fixed dollar amount, it states that both salary and start-up support will be recommended through the selection committee and aligned with the candidate’s experience, research plan, and goals. For a faculty recruit, that kind of runway can determine whether a program launches as a narrow survival exercise or as a fully equipped platform for high-risk cancer research. The ability to sustain expensive experiments in metabolism, immunology, and epigenetics often depends on exactly this kind of early institutional backing.
The opening also reflects a broader trend in oncology recruitment: institutions are increasingly hiring at the level of disease biology rather than by organ site alone. A molecular cancer program that spans signaling, chromatin regulation, and immune crosstalk can support work on resistance, biomarker discovery, and therapeutic vulnerability in a way that siloed recruitment often cannot. When diabetes or aging biology is folded into the portfolio, the department can also interrogate why tumors emerge, adapt, or evade control in physiologic contexts that shape cancer risk and treatment response. The same logic applies to neurosciences, where tumor-host interactions and systemic physiology may offer new angles on both cancer biology and survivorship.
One sentence captures the scale of the opportunity: this is a faculty search built for investigators who can move from mechanism to translation without losing rigor.
Research priorities reflect a translational cancer center strategy
The preferred research areas reveal how the department wants to define itself. Cancer metabolism and cancer signaling remain core drivers of therapeutic vulnerability, because malignant cells reprogram energy use and growth-factor pathways to sustain unchecked expansion. Epigenetics adds a layer of control over gene expression that can lock tumors into resistant phenotypes, while tumor immunology brings in the host response and the possibility of therapeutic redirection. Chemical biology broadens the toolkit, making it possible to design probes, inhibitors, and mechanistic experiments that link pathway biology to drug discovery.
That combination is not accidental. A department organized around those areas can support projects that track the same tumor phenotype from gene regulation to metabolic adaptation to immune escape. In oncology, those are rarely separate problems. They overlap at the bedside in patients whose disease evolves under treatment pressure, and they overlap at the bench in models that must explain why one pathway substitution or transcriptional state can produce resistance to an otherwise active therapy.
The inclusion of candidates working at the interfaces of cancer biology with diabetes, aging, and neuroscience is especially telling. Those areas point to a research culture that values systemic biology, where tumor behavior is understood in the context of host metabolism, tissue aging, and broader neurobiological signaling. In a center environment, that can open doors to cross-disciplinary collaborations that examine why cancer risk rises in specific physiologic states, why therapies behave differently across patient subgroups, and how non-malignant tissues influence treatment tolerance.
Applicants are expected to submit a complete curriculum vitae, a three- to five-year research plan limited to three pages, a teaching statement of up to two pages, and three to five references with contact details. The process begins immediately, with applications reviewed on a rolling basis until the positions are filled. Appointment is slated to begin as early as 2027, which gives the department time to assemble a cohort of hires rather than filling a single vacancy. For candidates, that timeline also suggests the institution is thinking in terms of long-term department building rather than short-term coverage.
The practical consequence is clear for both sides. For the university, this is a chance to shape a new academic unit around the biology of cancer itself. For applicants, the search offers a rare opening to enter a department that is still defining its research identity, with resources, center affiliation, and start-up support already part of the framework. The main unresolved issue is how the department will balance breadth and focus once the first hires arrive, and whether the eventual faculty mix will lean more heavily toward discovery biology, translational science, or a tightly integrated combination of both.